PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis
Your DNA May Explain Why Blood Thinners Work Differently for You
A meta-analysis of 39 studies involving 13,300 patients found that genetic polymorphisms (e.g., CES1, ABCB1) are associated with pharmacokin…
Tiny DNA differences may explain why the same blood thinner protects one person but causes bleeding in another.
Edoxaban monotherapy reduces adverse events compared to dual therapy in patients with atrial fibrillation and coronary artery disease.
One Blood Thinner May Be Safer Than Two for Heart Rhythm Patients
This secondary analysis of a randomized clinical trial evaluated 1,040 patients with atrial fibrillation and stable coronary artery disease.…
Taking just one blood thinner instead of two cuts the risk of death, stroke, or bleeding for heart patients with irregular rhythms.
DOACs show varied efficacy and safety profiles versus VKAs in atrial fibrillation patients with fall risk
Study compares blood thinners for atrial fibrillation patients with fall risk
A Bayesian network meta-analysis of 10 studies (5 RCTs, 5 observational) in AF patients with fall history/risk found apixaban ranked highest…
For atrial fibrillation patients at risk of falling, apixaban best prevents strokes while edoxaban best lowers major bleeding risks compared…
Edoxaban 12 months superior to 3 months for VTE prevention in cancer DVT, regardless of anemia status
For cancer patients with a leg blood clot and anemia, does longer treatment work better?
In this prespecified subgroup analysis of the ONCO DVT study, 12 months of edoxaban was superior to 3 months for preventing symptomatic recu…
Cancer patients with leg clots and anemia get better protection against new clots with 12 months of edoxaban compared to just 3 months, with…